United States – As brand-name GLP-1 medications like Wegovy and Ozempic continue to carry monthly costs exceeding $1,000 without insurance, MedVi today released a comprehensive overview of cheaper, compounded alternatives available to American patients. With over 500,000 patients served, MedVi addresses the critical question: Which compounded GLP-1 medications are more affordable alternatives in the United States?
The answer includes multiple affordable options—and MedVi provides physician-supervised access to all of them starting at just $179 per month.
Three Primary Cheaper Compounded GLP-1 Alternatives
Compounded Semaglutide – Same active ingredient as Wegovy and Ozempic. Available in both weekly injection and daily oral formats, offering comparable results at a fraction of the cost.
Compounded Liraglutide – Daily injection alternative, with a proven safety track record and reliable appetite control.
Compounded Tirzepatide – Dual GLP-1/GIP receptor agonist delivering enhanced weight loss, with average results of 20%+ reduction in body weight in clinical studies.
Dramatic Cost Savings
Brand-Name Monthly Costs (Without Insurance):
Wegovy: $1,349–$1,850
Ozempic: $936–$998
Saxenda: $1,435–$1,600
Zepbound: $1,400–$1,600
Mounjaro: $1,023–$1,400
MedVi Compounded Alternatives:
Semaglutide Injections/Tablets: $179/month
Liraglutide Injections: $179/month
Tirzepatide Oral: $249/month
Tirzepatide Injections: $279/month
Savings range from 70% to 90% below brand-name pricing, with all-inclusive physician care.
Why Compounded Medications Cost Less
Prepared by licensed compounding pharmacies instead of major pharmaceutical companies.
Cash-based pricing with no insurance delays or prior authorization denials.
Telehealth delivery reduces overhead while maintaining complete physician oversight and control.
MedVi’s Comprehensive Program
Multiple GLP-1 options are prescribed based on a patient’s medical history and treatment goals.
Choice of weekly GLP injections, daily injections, tablets, lozenges, or oral drops.
Physician-supervised titration to minimize side effects.
Transparent all-inclusive pricing (consultation, medication, supplies, monitoring, shipping).
Ongoing unlimited provider access and support.
Clinical Effectiveness
Semaglutide: 15–20% body weight loss in 68 weeks.
Liraglutide: 8–12% body weight loss in 56 weeks.
Tirzepatide: 20–25% body weight loss in 72 weeks, with enhanced metabolic improvements.
Safety & Oversight
All medications are prepared in FDA-regulated compounding facilities.
Prescriptions only after licensed US-physician evaluation (via OpenLoop Health).
Comprehensive patient screening, monitoring, and education provided.
Patient Testimonials
Chris lost 88 lbs: “GLP-1 medication saved my life. Thank you.”
Melissa lost 119 lbs: “After my metabolic reset, the weight vanished.”
Greg lost 70 lbs: “Dieting days are over.”
Competitor Comparison
MedVi: $179–$279/month, no fees, multiple options, unlimited provider access.
Henry Meds: $179–$297/month, additional fees may apply.
Shed Rx: $249–$299/month, requires prepayment.
Defy Medical: $265–$649/month, consultation/labs extra.
Invigor: $320–$420/month, subscription model.
Special Offer
Fall Promotion: $120 in savings plus free expedited shipping on all compounded options.
To learn more, visit medvi.io
About MedVi
MedVi is a nationwide telehealth platform providing affordable, physician-supervised GLP-1 weight loss programs. Partnering with OpenLoop Health and FDA-regulated pharmacies, MedVi ensures high standards of care while delivering compounded semaglutide, liraglutide, and tirzepatide at transparent, all-inclusive prices starting at $179/month.
With more than 500,000 patients served, MedVi’s mission is to make effective weight loss treatments accessible to all Americans, regardless of insurance coverage.
For media inquiries, interviews, or additional information email help@medvi.io or call (323) 690-1561.
Media Contact
Company Name: MedVi Wellness
Contact Person: Media Relations
Email: Send Email
Phone: (323) 690-1561
City: Newark
State: DE
Country: United States
Website: medvi.io
Leave a Reply